Observational studyJournal of the Pediatric Infectious Diseases Society2017
Pharmacokinetics of Darunavir/Ritonavir With Etravirine Both Twice Daily in Human Immunodeficiency Virus-Infected Adolescents and Young Adults.
Tim R Cressey, Ram Yogev, Andrew Wiznia, Rohan Hazra, Patrick Jean-Philippe, Bobbie Graham, Amy Gonzalez, Paula Britto, Vincent J Carey, Courtney V Fletcher and 2 more
Open access · bronzeAbstract readMulticenter StudyObservational Study
In one paragraphObservational study in Journal of the Pediatric Infectious Diseases Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 98% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors at 9 institutions in 2 countries.
Tim R CresseyProgram for HIV Prevention and Treatment, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Thailand.
Ram YogevChildren's Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Andrew WizniaJacobi Medical Center, Bronx, New York.
Rohan HazraNational Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development, Maternal and Pediatric Infectious Disease Branch.
Patrick Jean-PhilippeThe Henry M. Jackson Foundation-Division of AIDS, a Division of The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Contractor to National Institute of Allergy and Infectious Diseases, NIH, US Department of Health and Human Services, Bethesda, Maryland.
Bobbie GrahamFrontier Science & Technology, Amherst, New York.
Amy GonzalezFrontier Science & Technology, Amherst, New York.
Paula BrittoHarvard School of Public Health, Boston, Massachusetts.
Vincent J CareyHarvard School of Public Health, Boston, Massachusetts.
Courtney V FletcherUniversity of Nebraska Medical Center, Omaha.
Edward P AcostaUniversity of Alabama at Birmingham.
IMPAACT P1058A Team
Frontier Science & Technology Research Foundation · USHarvard University · USChiang Mai University · THEunice Kennedy Shriver National Institute of Child Health and Human Development · USJacobi Medical Center · USNational Institute of Allergy and Infectious Diseases · USNorthwestern University · USUniversity of Alabama at Birmingham · USUniversity of Nebraska Medical Center · US
Funding
LOC-IMPAACT Leadership GroupPharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant Women in the USUM1AI068632 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI Jennifer Jao, Sharon A Nachman · 2011 to 2026
$278.1MStatistical and Data Management Center-Pediatric,Adolescent, and Maternal CTGUM1AI068616 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Sean Scott Brummel, Marlene Ann Cooper · 2011 to 2026
$155.6MNIAID NIH HHS UM1 AI068616
6 · The paper itselfAbstract
Data on the combination of darunavir/ritonavir and etravirine both given twice daily in adolescents/young adults are lacking. In this study, we assessed the pharmacokinetics of darunavir/ritonavir 600/100 mg with etravirine 200 mg twice daily in 36 treatment-experienced human immunodeficiency virus-infected adolescents and young adults and found that exposures were comparable to those reported in adults.
Indexed as
AdolescentDarunavirDrug Administration ScheduleDrug CombinationsFemaleHIV InfectionsHIV Protease InhibitorsHumansMaleNitrilesPyridazinesPyrimidinesReverse Transcriptase InhibitorsRitonavirViral LoadYoung AdultDarunavirDrug CombinationsetravirineHIV Protease InhibitorsNitrilesPyridazinesPyrimidinesReverse Transcriptase InhibitorsRitonavirantiretroviralsdarunaviretravirinepediatricsritonavir
Identifiers
PMID27103489
PMCPMC5907875
OpenAlexW2336700562
What OpenQuestion holds
Textmetadata
Read underepoch 390